Nearly two-fifths (37 per cent) of Canadian employers cover glucagon-like peptide-1 therapies for both diabetes and weight loss, up from 31 per cent in 2025 and just 17 per cent in 2024, according to a new survey by the International Foundation of Employee Benefit Plans.

It found half (51 per cent) of employers said they cover the medications only for diabetes, down from 56 per cent last year and 66 per cent in 2024. A tenth (12 per cent) said they cover the drugs for other approved conditions, including sleep apnea and cardiovascular disease.

Read: Expanded use of GLP-1s a major driver of drug plan costs in 2026: report

Among employers offering weight-loss coverage, the vast majority (85 per cent) said they offer the........

© Benefits Canada